CELECOR COMPLETES SUBMISSION OF FDA NEW DRUG APPLICATION FOR INVESTIGATIONAL HEART-ATTACK DRUG

Filing follows release of positive Phase 3 study results for zalunfiban (DisaggproTM);company also appoints Chief Commercial OfficerDEL MAR, Calif., June 24, 2026 /PRNewswire/ — CeleCor Therapeutics has submitted the final section of its New Drug Application for the company's…

Read the full release →

News provided by PR Newswire.